Hematoxicity of Amodiaquine in Sprague-Dawley Rats

Jump To References Section

Authors

  • W. A. Saka
     Department of Physiology, College of Health Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo State ,NG
  • R. E. Akhigbe
     Department of Physiology, College of Health Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo State ,NG
  • A. O. Akinola
     Department of Physiology, College of Health Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo State ,NG
  • O. M. Azeez
     Department of Physiology, College of Health Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo State ,NG

Keywords:

Amodiaquine, hematological parameters, malaria, toxicity
Palaentology

Abstract

Objective: The use of amodiaquine (AQ) and its associated toxic effect has been a major public health concern since cases of life-threatening agranulocytosis and hepatic toxicity were reported during its prophylactic use. The objective of this study was to evaluate the hematological safety profile of AQ therapy. Materials and Methods: Sprague-Dawley rats were randomly distributed into four groups (n=5). Group 1 was the control, while groups 2, 3, and 4 received AQ treatment for 14 days at varying doses of 5 mg/kgBW, 10 mg/kgBW, and 15 mg/kgBW daily, respectively. Results: Following treatment, hematological variables were comparable in all groups (P>0.05). Conclusion: This study provides evidence to support the use of AQ in the treatment of uncomplicated malaria. However, to prevent emergence of local drug resistance, it should be used as part of a combination therapy. Monitoring for adverse effects is suggested.

Downloads

Download data is not yet available.

Downloads

Published

2018-05-25

How to Cite

Saka, W. A., Akhigbe, R. E., Akinola, A. O., & Azeez, O. M. (2018). Hematoxicity of Amodiaquine in Sprague-Dawley Rats. Toxicology International, 19(2), 112–114. Retrieved from http://www.informaticsjournals.com/index.php/toxi/article/view/21350

Issue

Volume 19, Issue 2, May-August 2012

Section

Original Research
Received 2018-05-24
Accepted 2018-05-24
Published 2018-05-25

 

References

AFHS. American Hospital Formulary Service. Drug information 88. In: McEvoy GK, editor. Bethesda, MD. 1988.

Winstanley P, Edwards G, Orme M, Breckenridge A. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol 1987;23:1-7.

Olliaro P, Mussano P. Amodiaquine for treating malaria. Cochrane Database Syst Rev 2003;(2):CD000016.

Rhodes EG, Ball J, Franklin IM. Amodiaquine induced agranulocytosis: Inhibition of colony growth in bone marrow by antimalarial agents. Br Med J (Clin Res Ed) 1986;292:717-8.

Ellis ME, Steed AJ, Addison GM. Neutropenia associated with dual antimalarial chemoprophylaxis; use of bone marrow culture as an aid in further drug management. J Infect 1987;15;147-52.

Clarke JB, Neftel K, Kitteringham NR, Park BK. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol 1991;95:369-75.

Akhigbe RE, Olatunji LA, Soladoye AO, Oyeyipo IP. Effect of angiotensin 1-converting enzyme inhibitor, captopril, on body weight and food and water consumption in oral contraceptivetreated rats. Am J Biochem Mol Biol 2011;1:95-100.

Akhigbe RE, Azeez OM, Ige SF, Oyeyipo IP, Ajao FO, Soladoye AO. Hemorheological effect of long-term administration of oral contraceptive in rats. Int J Pharmacol 2008;4:403-6.

Dacie SIV, Lewis SM. Practical haematology 7th ed. Livingston, London, Melborne and New York: J and A Churchill Ltd; 1991.

Joshi PK, Bose M, Harish D. Changes in certain haematological parameters in a siluroid catfish Clariasbatrachus (Linn) exposed to cadmium chloride. Pollution Resources 2002;22:129-131.

Molta NB, Oguche S, Pam SD, Omalu IC, Afolabi BM, Odujoko JB, et al. Amodiaquine treatment of uncomplicated malaria in children, in an area of chloroquine-resistant Plasmodium falciparum in north-central Nigeria. Ann Trop Med Parasitol 2003;97:663-9.

Massaga JJ, Lusingu JP, Makunde R, Malebo HM, Chile MM, Akida JA, et al. Biological and haematological safety profile of oral amodiaquine and chloroquine in healthy volunteers with or without Plasmodium falciparum infection in northeast Tanzania. Tanzan J Health Res 2008;10:144-50.

Luzzi GA, Peto TE. Adverse effects of antimalarials. An update. Drug Saf 1993;8:295-311.

Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 1996;348:1196-201.

Kremsner PG, Krishna S. Antimalarial combinations. Lancet 2004;364:285-94.

Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, et al. Amodiaquine alone, amodiaquine+sulfadoxinepyrimethamine, amodiaquine+artesunate, and artemetherlumefantrine for out patient treatment of malaria in Tanzanian children: A four-arm randomized effectiveness trial. Lancet 2005;365:1474-80.

Obua C, Gustafsson LL, Aguttu C, Anokbonggo WW, OgwalOkeng JW, Chiria J, et al. Improved efficacy with amodiaquine instead of chloroquine in sulfadoxine/pyrimethamine combination treatment of falciparum malaria in Uganda: Experience with fixeddose formulation. Acta Trop 2006;100:142-50.

Oyakhirome S, Pötschke M, Schwarz NG, Dörnemann J, Laengin M, Salazar CO, et al. Artesunate – amodiaquine combination therapy for falciparum malaria in young Gabonese children. Malar J 2007;6:29.

Ogungbamigbe TO, Ojurongbe O, Ogunro PS, Okanlawon BM, Kolawole SO. Chloroquine resistant Plasmodium falciparum malaria in Osogbo Nigeria: Efficacy of amodiaquine+sulfadoxinepyrimethamine and chloroquine+chlorpheniramine for treatment. Mem Inst Oswaldo Cruz 2008;103:79-84.

WHO. Position of WHO roll back malaria department on malaria treatment policy. Geneva: WHO; 2006. Available from: http://rbm.who.int/rbm/Attachment/20050418/ malariaTreatmentPolicyMarch2005.pdf] website 2003. [Last accessed on 2006 Jan 29].

Most read articles by the same author(s)